Ixazomib for the treatment of multiple myeloma

Paul G. Richardson, Sonja Zweegman, Elizabeth K. O’Donnell, Jacob P. Laubach, Noopur Raje, Peter Voorhees, Renda H. Ferrari, Tomas Skacel, Shaji K. Kumar, Sagar Lonial

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Introduction: Proteasome inhibitors (PIs) are among the backbones of multiple myeloma (MM) treatment; however, their long-term use can be limited by parenteral administration and treatment-related toxicities. Ixazomib, the first oral PI to enter the clinic, is approved around the world, in combination with lenalidomide and dexamethasone, for the treatment of patients with MM who have received at least one prior therapy. Areas covered: This review summarizes the clinical data leading to approval of ixazomib; its pharmacology, efficacy, and safety. Building on the data in relapsed/refractory MM (RRMM), it also reviews the available clinical trial data for ixazomib across the MM treatment algorithm in newly diagnosed MM, RRMM, and as maintenance therapy, and looks ahead to ongoing clinical trials and the expanding role of ixazomib in these indications. Expert opinion: Ixazomib is an efficacious and well-tolerated addition to the treatment armamentarium for RRMM, with benefit as a long-term, continuous therapy for all patients, including ‘poor prognosis’ patients, such as those with advanced stage disease, high-risk cytogenetic abnormalities, and elderly and frail patients. Data from ongoing clinical studies are expected to expand the role of ixazomib across the MM treatment algorithm and in a broader range of combination regimens.
Original languageEnglish
Pages (from-to)1949-1968
Number of pages20
JournalExpert Opinion on Pharmacotherapy
Volume19
Issue number17
Early online date2018
DOIs
Publication statusPublished - 22 Nov 2018

Cite this

Richardson, P. G., Zweegman, S., O’Donnell, E. K., Laubach, J. P., Raje, N., Voorhees, P., ... Lonial, S. (2018). Ixazomib for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy, 19(17), 1949-1968. https://doi.org/10.1080/14656566.2018.1528229
Richardson, Paul G. ; Zweegman, Sonja ; O’Donnell, Elizabeth K. ; Laubach, Jacob P. ; Raje, Noopur ; Voorhees, Peter ; Ferrari, Renda H. ; Skacel, Tomas ; Kumar, Shaji K. ; Lonial, Sagar. / Ixazomib for the treatment of multiple myeloma. In: Expert Opinion on Pharmacotherapy. 2018 ; Vol. 19, No. 17. pp. 1949-1968.
@article{d5042699bc7147f1915955a4a1bacab1,
title = "Ixazomib for the treatment of multiple myeloma",
abstract = "Introduction: Proteasome inhibitors (PIs) are among the backbones of multiple myeloma (MM) treatment; however, their long-term use can be limited by parenteral administration and treatment-related toxicities. Ixazomib, the first oral PI to enter the clinic, is approved around the world, in combination with lenalidomide and dexamethasone, for the treatment of patients with MM who have received at least one prior therapy. Areas covered: This review summarizes the clinical data leading to approval of ixazomib; its pharmacology, efficacy, and safety. Building on the data in relapsed/refractory MM (RRMM), it also reviews the available clinical trial data for ixazomib across the MM treatment algorithm in newly diagnosed MM, RRMM, and as maintenance therapy, and looks ahead to ongoing clinical trials and the expanding role of ixazomib in these indications. Expert opinion: Ixazomib is an efficacious and well-tolerated addition to the treatment armamentarium for RRMM, with benefit as a long-term, continuous therapy for all patients, including ‘poor prognosis’ patients, such as those with advanced stage disease, high-risk cytogenetic abnormalities, and elderly and frail patients. Data from ongoing clinical studies are expected to expand the role of ixazomib across the MM treatment algorithm and in a broader range of combination regimens.",
author = "Richardson, {Paul G.} and Sonja Zweegman and O’Donnell, {Elizabeth K.} and Laubach, {Jacob P.} and Noopur Raje and Peter Voorhees and Ferrari, {Renda H.} and Tomas Skacel and Kumar, {Shaji K.} and Sagar Lonial",
year = "2018",
month = "11",
day = "22",
doi = "10.1080/14656566.2018.1528229",
language = "English",
volume = "19",
pages = "1949--1968",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "17",

}

Richardson, PG, Zweegman, S, O’Donnell, EK, Laubach, JP, Raje, N, Voorhees, P, Ferrari, RH, Skacel, T, Kumar, SK & Lonial, S 2018, 'Ixazomib for the treatment of multiple myeloma' Expert Opinion on Pharmacotherapy, vol. 19, no. 17, pp. 1949-1968. https://doi.org/10.1080/14656566.2018.1528229

Ixazomib for the treatment of multiple myeloma. / Richardson, Paul G.; Zweegman, Sonja; O’Donnell, Elizabeth K.; Laubach, Jacob P.; Raje, Noopur; Voorhees, Peter; Ferrari, Renda H.; Skacel, Tomas; Kumar, Shaji K.; Lonial, Sagar.

In: Expert Opinion on Pharmacotherapy, Vol. 19, No. 17, 22.11.2018, p. 1949-1968.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Ixazomib for the treatment of multiple myeloma

AU - Richardson, Paul G.

AU - Zweegman, Sonja

AU - O’Donnell, Elizabeth K.

AU - Laubach, Jacob P.

AU - Raje, Noopur

AU - Voorhees, Peter

AU - Ferrari, Renda H.

AU - Skacel, Tomas

AU - Kumar, Shaji K.

AU - Lonial, Sagar

PY - 2018/11/22

Y1 - 2018/11/22

N2 - Introduction: Proteasome inhibitors (PIs) are among the backbones of multiple myeloma (MM) treatment; however, their long-term use can be limited by parenteral administration and treatment-related toxicities. Ixazomib, the first oral PI to enter the clinic, is approved around the world, in combination with lenalidomide and dexamethasone, for the treatment of patients with MM who have received at least one prior therapy. Areas covered: This review summarizes the clinical data leading to approval of ixazomib; its pharmacology, efficacy, and safety. Building on the data in relapsed/refractory MM (RRMM), it also reviews the available clinical trial data for ixazomib across the MM treatment algorithm in newly diagnosed MM, RRMM, and as maintenance therapy, and looks ahead to ongoing clinical trials and the expanding role of ixazomib in these indications. Expert opinion: Ixazomib is an efficacious and well-tolerated addition to the treatment armamentarium for RRMM, with benefit as a long-term, continuous therapy for all patients, including ‘poor prognosis’ patients, such as those with advanced stage disease, high-risk cytogenetic abnormalities, and elderly and frail patients. Data from ongoing clinical studies are expected to expand the role of ixazomib across the MM treatment algorithm and in a broader range of combination regimens.

AB - Introduction: Proteasome inhibitors (PIs) are among the backbones of multiple myeloma (MM) treatment; however, their long-term use can be limited by parenteral administration and treatment-related toxicities. Ixazomib, the first oral PI to enter the clinic, is approved around the world, in combination with lenalidomide and dexamethasone, for the treatment of patients with MM who have received at least one prior therapy. Areas covered: This review summarizes the clinical data leading to approval of ixazomib; its pharmacology, efficacy, and safety. Building on the data in relapsed/refractory MM (RRMM), it also reviews the available clinical trial data for ixazomib across the MM treatment algorithm in newly diagnosed MM, RRMM, and as maintenance therapy, and looks ahead to ongoing clinical trials and the expanding role of ixazomib in these indications. Expert opinion: Ixazomib is an efficacious and well-tolerated addition to the treatment armamentarium for RRMM, with benefit as a long-term, continuous therapy for all patients, including ‘poor prognosis’ patients, such as those with advanced stage disease, high-risk cytogenetic abnormalities, and elderly and frail patients. Data from ongoing clinical studies are expected to expand the role of ixazomib across the MM treatment algorithm and in a broader range of combination regimens.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85057548260&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30422008

U2 - 10.1080/14656566.2018.1528229

DO - 10.1080/14656566.2018.1528229

M3 - Article

VL - 19

SP - 1949

EP - 1968

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 17

ER -

Richardson PG, Zweegman S, O’Donnell EK, Laubach JP, Raje N, Voorhees P et al. Ixazomib for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy. 2018 Nov 22;19(17):1949-1968. https://doi.org/10.1080/14656566.2018.1528229